Myasthenia Gravis: all 327 studies

Page 2 of 4. Open to participants first (144), then studies with results posted, then the rest; newest registration first within each.

• National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaRecruitingNCT06443333
• Patient Observation With Environmental and Wearable Sensors in Myasthenia GravisRecruitingNCT06441825
• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisEnrolling by invitationNCT06435312Phase 3
• Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia GravisRecruitingNCT06414954Phase 2
• A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingNCT06392386Phase 2/3
• Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia GravisRecruitingNCT06371040Phase 1
• RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisRecruitingNCT06359041Phase 1/2
• Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.RecruitingNCT06342544Phase 3
• Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644
• A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.RecruitingNCT06299748
• A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod AlfaRecruitingNCT06298565
• Physical Activity Monitoring in Myasthenia GravisRecruitingNCT06277830
• MuSK Myasthenia 1000 StudyRecruitingNCT06259071
• A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyRecruitingNCT06249438Phase 1
• Myasthenia Gravis Registry in ChinaRecruitingNCT06241521
• Perioperative Efgartigimod for Thymoma and Myasthenia GravisNot yet recruitingNCT06221501Phase 2
• KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisRecruitingNCT06193889Phase 2/3
• Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia GravisRecruitingNCT06064695Not applicable
• Vitaccess Real MG RegistryRecruitingNCT06064461
• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisRecruitingNCT06055959Phase 2/3
• A Prospective Cohort Study of Myasthenia Gravis in ChinaRecruitingNCT06006832
• Pyridostigmine and Amifampridine for Myasthenia GravisRecruitingNCT05919407Phase 3
• Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia GravisEnrolling by invitationNCT05888558
• Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)RecruitingNCT05868837Phase 3
• Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia GravisRecruitingNCT05828225Phase 1
• Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisRecruitingNCT05716035Phase 2/3
• Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesRecruitingNCT05635266
• The ME&MG Digital Solution for Autonomous Assessment of Myasthenia GravisRecruitingNCT05564936Not applicable
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisEnrolling by invitationNCT05374590Phase 2/3
• Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia GravisRecruitingNCT05337891
• A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisRecruitingNCT05265273Phase 2/3
• Predictors and Prognostic Factors of Myasthenia Gravis OutcomeRecruitingNCT05214612
• Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Phase 2
• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Phase 3Results posted
• Study of Myasthenic Crisis in ChinaRecruitingNCT04837625
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisRecruitingNCT04833894Phase 2/3
• Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruitingNCT04806620
• Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemRecruitingNCT04561557Early Phase 1
• Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in ChinaRecruitingNCT04535843
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)RecruitingNCT04202341
• TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyRecruitingNCT04182984
• The EXPLORE MG Registry for Myasthenia GravisRecruitingNCT03792659
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT01793168
• Serum Auto-Antibodies in Neurological DiseasesEnrolling by invitationNCT00704626
• A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisCompletedNCT06471361Phase 3Results posted
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Phase 3Results posted
• A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)CompletedNCT05681715Phase 3Results posted
• An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 InhibitorsCompletedNCT05514873Phase 3Results posted
• Acupuncture in Myasthenia Gravis (AcuMG)CompletedNCT05230082Not applicableResults posted
• Study of ALXN2050 in Adult Participants With Generalized Myasthenia GravisTerminatedNCT05218096Phase 2Results posted
• SP Thoracic IDE StudyActive, not recruitingNCT05150210Not applicableResults posted
• Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia GravisTerminatedNCT05132569Phase 3Results posted
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia GravisCompletedNCT04980495Phase 3Results posted
• A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Phase 3Results posted
• Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia GravisCompletedNCT04818671Phase 3Results posted
• Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisCompletedNCT04735432Phase 3Results posted
• Clinical Trial Comparing Two Non-Surgical Treatments for Severe BlepharoptosisCompletedNCT04678115Not applicableResults posted
• A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisCompletedNCT04650854Phase 3Results posted
• Myasthenia Gravis Inebilizumab TrialActive, not recruitingNCT04524273Phase 3Results posted
• A Study of TAK-079 in People With Generalized Myasthenia GravisCompletedNCT04159805Phase 2Results posted
• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT04124965Phase 3Results posted
• Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04115293Phase 3Results posted
• A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT03971422Phase 3Results posted
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia GravisCompletedNCT03920293Phase 3Results posted
• An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia GravisTerminatedNCT03896295Phase 2Results posted
• A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsCompletedNCT03863080Phase 2Results posted
• Clinical Trial to Improve the Magnetic Levator ProsthesisCompletedNCT03818204Not applicableResults posted
• A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia GravisCompletedNCT03772587Phase 2Results posted
• A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.CompletedNCT03770403Phase 3Results posted
• A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)CompletedNCT03759366Phase 3Results posted
• An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT03669588Phase 3Results posted
• Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)TerminatedNCT03579966Phase 3Results posted
• Disease-Modifying Treatments for Myasthenia GravisCompletedNCT03490539Results posted
• Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisCompletedNCT03315130Phase 2Results posted
• Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGCompletedNCT03304054Phase 3Results posted
• Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia GravisCompletedNCT03052751Phase 2Results posted
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT02965573Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisCompletedNCT02950155Phase 3Results posted
• Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia GravisCompletedNCT02565576Phase 2Results posted
• Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisCompletedNCT02473965Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisCompletedNCT02473952Phase 2Results posted
• A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsCompletedNCT02413580Phase 3Results posted
• Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisCompletedNCT02301624Phase 3Results posted
• BeatMG: Phase II Trial of Rituximab In Myasthenia GravisCompletedNCT02110706Phase 2Results posted
• Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisCompletedNCT02100969Phase 2Results posted
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)CompletedNCT01997229Phase 3Results posted
• The Evaluation of Belimumab in Myasthenia Gravis (MG)CompletedNCT01480596Phase 2Results posted
• Efficacy of Prednisone In the Treatment of Ocular MyastheniaTerminatedNCT00995722Phase 3Results posted
• Efficacy of Methotrexate in Myasthenia GravisCompletedNCT00814138Phase 2Results posted
• Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisTerminatedNCT00727194Phase 2Results posted
• Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia GravisTerminatedNCT00424489Phase 1Results posted
• Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone TherapyCompletedNCT00294658Phase 3Results posted
• Depressive Tendency and Counseling Outcomes in Thymoma-Associated MGCompletedNCT07649187Not applicable
• Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.CompletedNCT07532707Not applicable
• Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia GravisCompletedNCT07472777
• Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous PatientsCompletedNCT07319689
• Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Health BMI Learning ProgramCompletedNCT07291713Not applicable
• A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese ParticipantsCompletedNCT07154095Phase 1
• Rituximab for the Treatment of New-onset AChR-Myasthenia GravisActive, not recruitingNCT07071246Not applicable
• Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia GravisCompletedNCT07022028

← Myasthenia Gravis overview